Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has revealed the 25 recipients of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. 20 scholarships will go to individuals with Duchenne, while 5 will be awarded to siblings of Duchenne patients. This marks the eighth year of the program, designed to support those affected by Duchenne muscular dystrophy. The company's announcement did not specify the amount of each scholarship or the total financial commitment for this year.